Results 11 to 20 of about 12,412 (210)

Cutaneous Vasculitis During Secukinumab Treatment [PDF]

European Journal of Case Reports in Internal Medicine, 2020
Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis.
Camila da Silva Cendon Duran, Mittermayer Barreto Santiago   +1 more
doaj   +2 more sources

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To evaluate the efficacy and safety of Secukinumab versus Adalimumab in the treatment of the moderate to severe plaque psoriasis. Methods A total of 90 patients with moderate to severe psoriasis were randomly divided into three groups ...
Dandan HU, Peimiao ZHANG
doaj   +1 more source

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study

Chinese Medical Journal, 2021
. Background:. There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.
Yan Zhao, Lin Cai, Xiao-Yang Liu, Heng Zhang, Jian-Zhong Zhang, Li-Shao Guo   +5 more
doaj   +1 more source

Active pulmonary tuberculosis in a patient with secukinumab treatment

Radiology Case Reports, 2023
Numerous investigations have documented active tuberculosis (TB) infection following biologic treatment. One of the most secure biologic medications for infections is secukinumab.
Cao Thanh Ngoc, MD, PhD, Bui Dang Khoa, MD, Huynh Khoi Nguyen, MD, Le Bao Le, MD, Dang Vinh Hiep, MD, PhD, Nguyen Minh Duc, MD   +5 more
doaj   +1 more source

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

ACR Open Rheumatology, 2020
Objective Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years.
Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards, Susanne Rohrer, the MEASURE 3 study group   +11 more
doaj   +1 more source

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

Vaccines, 2022
Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis.
Paolo Gisondi, Davide Geat, Martina Maurelli, Luca Degli Esposti, Francesco Bellinato, Giampiero Girolomoni   +5 more
doaj   +1 more source

Secukinumab Therapy in Psoriasis Management [PDF]

, 2022
Background : In recent years, use of biological therapy in psoriasis has increased as a result of advances in understanding the pathophysiology of psoriasis disease.
Ira Yunita, Sylvia Anggraeni
core   +2 more sources

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review

Rheumatology and Therapy, 2019
Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States.
Prashanth Sunkureddi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Peter Hur, Reeti Joshi   +5 more
doaj   +1 more source

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)

RMD Open, 2023
Background Secukinumab efficacy and retention data are emerging in patients with axial spondyloarthritis (axSpA) in real-world settings. However, limited data are available on the predictive factors that affect the retention rate.
Maxime Dougados, Pascal Claudepierre, Adeline Ruyssen-Witrand, Philippe Goupille, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas, Julien Lucas, Emilie Desfleurs   +9 more
doaj   +1 more source

Secukinumab: Drug Survival in Clinical Practice Settings

, 2021
Secukinumab, an immunoglobulin G1/ monoclonal antibody that selectively targets interleukin 17a, is used to treat moderate to severe plaque psoriasis in adults who are eligible for systemic treatment.
Martínez-Pilar, L., Ruiz-Villaverde, Ricardo, Rodriguez Fernández-Freire, L., Armario Hita, José Carlos, Galán-Gutiérrez, Manuel   +4 more
core   +2 more sources